Alembic Pharmaceuticals Limited (APLLTD) has received a vote of confidence from CRISIL Ratings Limited, as the credit rating agency reaffirmed the company's AA+/Stable credit rating for its bank loan facilities. This development comes with an increase in the rated amount from Rs. 600.00 crores to Rs. 800.00 crores, while maintaining the company's overall borrowing limit.

Credit Rating Details

CRISIL Ratings Limited has provided the following rating for Alembic Pharmaceuticals:

The AA+ rating indicates a high degree of safety regarding timely servicing of financial obligations and very low credit risk. The 'Stable' outlook suggests that the rating is likely to remain unchanged in the medium term.

Implications of the Rating

The reaffirmation of the AA+/Stable rating reflects CRISIL's continued confidence in Alembic Pharmaceuticals' financial strength and stability. The enhancement of the rated amount from Rs. 600.00 crores to Rs. 800.00 crores, without changing the overall borrowing limit, suggests that the company has gained additional flexibility in its financing options.

Recent Developments

In addition to the credit rating news, Alembic Pharmaceuticals has recently achieved a significant milestone in its product portfolio. The company announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Carbamazepine Extended-Release Tablets USP, in strengths of 100 mg, 200 mg, and 400 mg.

This approval is noteworthy as:

• The approved ANDA is therapeutically equivalent to Novartis Pharmaceuticals Corporation's Tegretol-XR Extended-Release Tablets.
• Carbamazepine Extended-Release Tablets are indicated for use as an anticonvulsant and for treating pain associated with true trigeminal neuralgia.
• The estimated market size for these tablets is US$ 71.00 million for the twelve months ending March 2025, according to IQVIA data.

Company Profile

Alembic Pharmaceuticals Limited, founded in 1907, is a vertically integrated research and development pharmaceutical company. The company is publicly listed and specializes in manufacturing and marketing generic pharmaceutical products globally. With state-of-the-art research and manufacturing facilities approved by regulatory authorities of many developed countries, including the USFDA, Alembic Pharmaceuticals has established itself as a leader in branded generics in India.

The reaffirmation of its credit rating, along with the recent USFDA approval, underscores Alembic Pharmaceuticals' strong market position and its continued focus on growth and expansion in the pharmaceutical sector.

Alembic Pharmaceuticals Limited (APL) has received a vote of confidence from CRISIL Ratings Limited, as the credit rating agency reaffirmed the company's AA+/Stable credit rating for its bank loan facilities. This development comes with an enhancement in the rated amount from Rs. 600.00 crores to Rs. 800.00 crores, while maintaining the company's overall borrowing limit.

Credit Rating Reaffirmation

The reaffirmation of the AA+/Stable rating applies to Alembic Pharmaceuticals' long-term bank loan facilities. This rating indicates a high degree of safety regarding timely servicing of financial obligations and very low credit risk, reflecting the company's strong financial position and creditworthiness.

Enhanced Loan Limit

While the rated amount has been increased by Rs. 200.00 crores, it's important to note that the company's overall borrowing limit remains unchanged. This suggests that Alembic Pharmaceuticals has restructured its borrowing mix, potentially to optimize its financial strategy.

Company's Disclosure

In compliance with regulatory requirements, Alembic Pharmaceuticals has formally notified the stock exchanges about this development. As per the LODR (Listing Obligations and Disclosure Requirements) data, the company stated:

"CRISIL Ratings Limited (CRISIL) vide its letter dated 25th July, 2025, has reaffirmed its Credit Rating on Bank Loan facilities with Enhanced Limits. Although, our rating amount for the following category of borrowing have been enhanced, the overall borrowing limit remains unchanged."

Recent Developments

It's worth noting that Alembic Pharmaceuticals has been making strides in its pharmaceutical business. According to the LODR data, the company recently received US Food & Drug Administration (USFDA) Final Approval for Carbamazepine Extended-Release Tablets USP in various strengths. This approval adds to the company's growing portfolio of ANDA (Abbreviated New Drug Application) approvals, which now stands at a cumulative total of 225, including 202 final approvals and 23 tentative approvals from the USFDA.

The reaffirmation of Alembic Pharmaceuticals' credit rating, along with the enhanced loan limit and recent regulatory approvals, indicates the company's solid financial footing and ongoing growth in its pharmaceutical operations. These developments may position the company well for future expansion and market opportunities in the pharmaceutical sector.